Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET
- PMID: 36873926
- PMCID: PMC9983143
- DOI: 10.1002/trc2.12372
Development, initial validation, and application of a visual read method for [18F]MK-6240 tau PET
Abstract
Background: The positron emission tomography (PET) radiotracer [18F]MK-6240 exhibits high specificity for neurofibrillary tangles (NFTs) of tau protein in Alzheimer's disease (AD), high sensitivity to medial temporal and neocortical NFTs, and low within-brain background. Objectives were to develop and validate a reproducible, clinically relevant visual read method supporting [18F]MK-6240 use to identify and stage AD subjects versus non-AD and controls.
Methods: Five expert readers used their own methods to assess 30 scans of mixed diagnosis (47% cognitively normal, 23% mild cognitive impairment, 20% AD, 10% traumatic brain injury) and provided input regarding regional and global positivity, features influencing assessment, confidence, practicality, and clinical relevance. Inter-reader agreement and concordance with quantitative values were evaluated to confirm that regions could be read reliably. Guided by input regarding clinical applicability and practicality, read classifications were defined. The readers read the scans using the new classifications, establishing by majority agreement a gold standard read for those scans. Two naïve readers were trained and read the 30-scan set, providing initial validation. Inter-rater agreement was further tested by two trained independent readers in 131 scans. One of these readers used the same method to read a full, diverse database of 1842 scans; relationships between read classification, clinical diagnosis, and amyloid status as available were assessed.
Results: Four visual read classifications were determined: no uptake, medial temporal lobe (MTL) only, MTL and neocortical uptake, and uptake outside MTL. Inter-rater kappas were 1.0 for the naïve readers gold standard scans read and 0.98 for the independent readers 131-scan read. All scans in the full database could be classified; classification frequencies were concordant with NFT histopathology literature.
Discussion: This four-class [18F]MK-6240 visual read method captures the presence of medial temporal signal, neocortical expansion associated with disease progression, and atypical distributions that may reflect different phenotypes. The method demonstrates excellent trainability, reproducibility, and clinical relevance supporting clinical use.
Highlights: A visual read method has been developed for [18F]MK-6240 tau positron emission tomography.The method is readily trainable and reproducible, with inter-rater kappas of 0.98.The read method has been applied to a diverse set of 1842 [18F]MK-6240 scans.All scans from a spectrum of disease states and acquisitions could be classified.Read classifications are consistent with histopathological neurofibrillary tangle staging literature.
Keywords: Alzheimer's disease; MK‐6240; [18F]MK‐6240; florquinitau; neurofibrillary tangles; positron emission tomography; tau; tracer; visual read.
© 2023 The Authors. Alzheimer's & Dementia: Translational Research & Clinical Interventions published by Wiley Periodicals LLC on behalf of Alzheimer's Association.
Conflict of interest statement
J. Shuping is a consultant to Enigma Biomedical Group. C. Wilde was a consultant to Cerveau Technologies. J. Evelhoch, W. Kreisl, K. Johnson, C. Rowe, and K. Van Laere are consultants/advisors to Cerveau Technologies. D. Matthews, A. Lukic, and R. Andrews are employees of ADM Diagnostics, Inc. D. Scott, K. Adamczuk, J. Barakos, and D. Purcell are employees of Clario. C. Rowe is an employee of Austin Health, Melbourne and University of Melbourne, Australia. S. Johnson is an employee of the University of Wisconsin Madison. W. Kreisl, A. Brickman, D. Devanand, J. Luchsinger, Y. Stern, and P. Lao are employees of Columbia University. P. Rosa‐Neto is an employee of McGill University. K. Van Laere is an employee of UZ Leuven. K. Johnson and J. Price are employees of Massachusetts General Hospital and Harvard University. A. Boxer is an employee of the University of California San Francisco. W. Klunk is an employee of the University of Pittsburgh. C. Sur was an employee of Merck & Co., Inc. L. Cordes is an employee of StatKing Clinical Services. L. Ward is an employee of Florey Department of Neuroscience and Mental Health and University of Melbourne. S. Mathotaarachchi is an employee of Enigma Biomedical Group. Author disclosures are available in the supporting information.
Figures
References
-
- Arriagada PV, Growdon JH, Hedley‐Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992a;42:631‐639. - PubMed
-
- Walji AM, Hostetler ED, Selnick H, et al. Discovery of 6‐(Fluoro‐(18)F)‐3‐(1H‐pyrrolo[2,3‐c]pyridin‐1‐yl)isoquinolin‐5‐amine ([(18)F]‐MK‐6240): a positron emission tomography (PET) imaging agent for quantification of neurofibrillary tangles (NFTs). J Med Chem. 2016;59:4778‐4789. - PubMed
Grants and funding
- R01 AG063888/AG/NIA NIH HHS/United States
- R01 AG050440/AG/NIA NIH HHS/United States
- K24 AG045334/AG/NIA NIH HHS/United States
- R01 AG050436/AG/NIA NIH HHS/United States
- R01 AG062167/AG/NIA NIH HHS/United States
- R01 AG055299/AG/NIA NIH HHS/United States
- R01 AG052414/AG/NIA NIH HHS/United States
- P01 AG025204/AG/NIA NIH HHS/United States
- R01 AG055422/AG/NIA NIH HHS/United States
- R00 AG065506/AG/NIA NIH HHS/United States
- K23 AG052633/AG/NIA NIH HHS/United States
- R01 AG038465/AG/NIA NIH HHS/United States
- R01 AG021155/AG/NIA NIH HHS/United States
- RF1 AG058067/AG/NIA NIH HHS/United States
- RF1 AG027161/AG/NIA NIH HHS/United States
- R01 AG062285/AG/NIA NIH HHS/United States
- P30 AG062715/AG/NIA NIH HHS/United States
- RF1 AG051556/AG/NIA NIH HHS/United States
LinkOut - more resources
Full Text Sources